Obstetrics, Gynecology and Reproduction

Advanced search
Vol 4, No 3 (2010)


6-11 141
Endometriosis is a pathological process which is characterized by growth and development of tissue resembling the endometrium by its structure and function, while localizing beyond its normal site within the mucous membrane of uterine body. Endometriosis is one of the most topical issues of modern medicine. Regarding mechanisms of endometriosis occurrence, there are various, sometimes mutually exclusive points of view. Thus, over 10 theories of endometriosis origin are known, though none of those can comprehensively explain the multiplicity of manifestation and localization of endometriosis. The lead clinical manifestations of endometriosis are pain syndrome (dysmenorrhea, dyspareunia, dyschezia, etc.) and infertility. One of the main endometriosis treatment methods is surgery, particularly the low-invasive surgery. Surgical methods of treatment are often extra radical for young females and leads to castration syndrome in patients of reproductive and pre-menopausal age, and may well be of low efficacy regardless of surgical tactics. The main principle of medicinal therapy using any hormonal agent is the suppression of estradiol secretion by ovaries. The basis for hormonal therapy is formed by application of progestagens, anti-gestagens and gonadoliberin agonists
12-20 77
Purpose: it was concluded in revealing the particularities hemolymphocirculation in pool of the small pelvic at exacerbation of the chronic inflammation beside woman's and study efficiency to their correction with use lymphogenic technology. Define clinical and morphological criteria of scar after caesarean section to form the groups pregnant for the following vaginal labor. Methodology: prospective study. Subjects: 314 women with chronic pelvic inflammatory disease in stage of the intensification. Methods: reolymphovasography for quantitative and qualitative estimation of the factors lymphodinamic on 1, 5 and 7 day of the treatment. Teplovizion study by means of teplovizor IFP-M in mode of the real time. The range of the temperature 25-41оС, limiting sensitivity of the instrument not less 0,1оС. The scene of the heat relief registered in projections pelvic organ in hypogastric`s area. Results: Under chronic inflammation organ small basin in stage of the intensification occurred the reduction of the arterial influx in region of the small basin in 2-6 once, increase venous and lymphatic current in 1,5-3 times, increasing of the kinetic resistance in arterial riverbed and reduction in venous-lymphatic section, as well as reduction in 1,3-3,5 times. Herewith time of the filling microcirculation and venous riverbed. Use lymphogenic technology in correction of the chronic pelvic inflammatory disease brought about increase the arterial influx in small basin on 23%, time of the microcirculatory and venous division on 36%, initial and final velocity of the influx in 1,4 times, velocities and volume venous and lymphatic filling on 13-14%. When change the cofrom-carryings arterial, venous and lymphatic section approached to factor beside «practically normal» women. The offered diagnostic criteria degrees to insufficiency hemolymphocirculation in pool of the small basin under chronic inflammation in stage of the intensification beside women, as new on given reolymphovasography and remote teplovizion studies have allowed to value the condition an hemolymphocirculation in region. Conclusion: Marketed in persisting work approach to treatment of the chronic pelvic inflammatory diseases with use of lymphogenic technology has shown pathogenetic directivity of the applying methods and, as effect, this high clinical efficiency, and as a result of reduction inflammatory process when recovering hemolymphocirculation in region of the small pelvic. The method of reolymphovasography for op-remissions of the breaches hemolymphocirculation in pool of the small basin is criterion to efficiency treatments chronic pelvic inflammatory disease
21-24 127
Chronic endometritis (CE) - a common disease with no unified concept of pathogenesis, characterized by undulating and ever-progressive pathological process. Important pathogenic factors contributing to the development of CE, is immune deficiency and violation of endometrium angioarchitectonics. Currently has been widely discussed question of the pro- and antioxidant systems imbalance role in the pathogenesis of HE. From these positions, it is obvious that the stimulation of natural antioxidant systems, introduction of exogenous antioxidants - one of the essential moments in the treatment of CE. Actovegin is a one of the modern drugs which is best meets the requirements of CE pathogenic-based therapy and has an impact on the above links of pathogenesis. Actovegin contains components with high biological activity: amino acids, oligopeptides, nucleosides, oligosaccharides and glycolipides, enzymes, electrolytes, and a number of important macro- and micronutrients. Exacerbation of already existing chronic inflammation often occurs after an abortion and therapeutic surgical procedures. Therefore, an important measure to prevent the exacerbation of chronic endometritis, an essential part of the treatment of post-abortion or postpartum CE, treatment and diagnostic curettage is the rehabilitation of structural and functional state of the endometrium with the use of Actovegin.
25-28 94
Great scientific and practical interest in the approach to therapy and prevention of isolated urogenital disorders caused by estrogen deficiency. Drug of choice for treating and preventing urogenital disorders is estrogenobuslovlennyh Ovestin containing estriol in sufficient therapeutic dosage. After the treatment course is shown the transition to supportive / preventive dose to prevent the resumption of symptoms. Climacteric syndrome with increasing life expectancy and the proportion of elderly in the population is a growing problem in women's health. Therapeutic and prophylactic approaches to urogenital disorders which were caused by estrogens deficit are present great interest. Ovestin containing estriol in sufficient therapeutic dosage is drug of choice for therapy and prevention of estrogen-related urogenital disorders. After the treatment course with Ovestin transition on supportive/ prophylactic dose is recommended for prevention of renewal of UGD symptoms.

ISSN 2313-7347 (Print)
ISSN 2500-3194 (Online)